Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Rozzano – page 204

2 815 clinical trials in Rozzano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Rozzano at a glance
2 815
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 815 trials in Rozzano

Open in trial search

Chronic lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Thrombotic thrombocytopenic purpura

Not recruiting

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Caplacizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Adrenogenital syndrome

Not recruiting

Study on the Safety and Effectiveness of Crinecerfont for Adults with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Primary biliary cholangitis

Not recruiting

Study on the Long-Term Safety of Seladelpar for Patients with Primary Biliary Cholangitis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Neoplasm

Not recruiting

Study on the Effectiveness of Inavolisib, Atezolizumab, and Entrectinib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Novartis Pharma AG

Warm autoimmune haemolytic anaemia

Not recruiting

Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Hepatocellular carcinoma

Not recruiting

Study on Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer Not Treatable by Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study of Lutetium (177Lu) Edotreotide compared to standard treatment in patients with aggressive Grade 2 and Grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:ITM Solucin GmbH

Immune thrombocytopenia

Not recruiting

Study Comparing Romiplostim and Dexamethasone with Dexamethasone Alone for Patients with Newly Diagnosed Primary Immune Thrombocytopenia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Rozzano

What the registry says about research in the country

01 Oncology Research

Critical investigations focusing on various cancer types including metastatic colorectal cancer, acute myeloid leukemia, and advanced breast cancer. Studies evaluate novel therapeutic combinations and targeted treatments to improve patient outcomes.

  • Gastric and Gastroesophageal Cancer Treatments
  • Breast Cancer Therapies
  • Blood Cancer Interventions

Multiple trials exploring innovative treatment approaches for both solid tumors and hematological malignancies.

02 Respiratory and Pulmonary Studies

Research initiatives examining treatments for idiopathic pulmonary fibrosis and chronic respiratory conditions. Studies focus on improving lung function and patient quality of life.

  • Pulmonary Fibrosis Management
  • Chronic Rhinosinusitis Treatment

Investigations aim to advance therapeutic options for patients with chronic respiratory conditions.

03 Autoimmune and Inflammatory Diseases

Comprehensive research into conditions like psoriatic arthritis and systemic sclerosis. Studies evaluate new biological treatments and therapeutic approaches.

  • Inflammatory Bowel Diseases
  • Skin and Joint Conditions
  • Immune System Disorders

Trials focus on developing targeted therapies for various inflammatory conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.